Silver Book Fact

“Knowing that his disease had a high cure rate, Ben Dacus felt a sense of security at a time of great uncertainty. In 1988 he was diagnosed with Hodgkin’s disease.

Strangely enough, Ben’s reaction to his diagnosis was one of relief. ‘I was relieved to know my illness had a name, and because of the high cure rate, I never really feared that I was going to die. Hodgkin’s had a long history of research, and doctors had been treating it succesfully for many year.’

When radiation treatments didn’t work, Ben was devastated. But to his relief chemotherapy afforded him a rapid recovery.

Looking back on his illness, Ben says he is thankful for medical research. ‘It didn’t occur to me at the time I was going through treatment to consider how medical research had brought treatment methods to the point it had. But I was thankful to live in a day and age when cancer is treatable. If it had been the 1950s, I would have died four years later.”

Investment in Research Saves Lives and Money. http://www.researchamerica.org/advocacy/investment.html. Published 2005

Reference

Title
Investment in Research Saves Lives and Money
Publisher
Research!America
Publication Date
Published 2005
Authors
Research!America
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Every additional dollar spent on newer, less toxic hormonal therapy for breast cancer patients has produced health gains valued at between $27.03 and $36.81.  
  • Since Congress passed the National Cancer Act in 1971, the percentage of the U.S. population living with, through, or beyond a cancer diagnosis has more than tripled.  
  • According to the Pharmaceutical Research and Manufacturers of America, researchers are currently working on 646 medicines for cancer. All are either in clinical trials or under FDA review. …  
  • As of July 2014, 18 anticancer drugs received FDA approval after being designated breakthrough therapies.  
  • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets CA125, a surface protein, or antigen, that is released in excess quantities by some ovarian cancers.…